Ardelyx Inc (ARDX NASDAQ) stock market data APIs
$6.9967
0.12(1.7%)
as of May 7, 2026
Try our APIs with
free plan!
Ardelyx Inc Financial Data Overview
Price chart is built with
Anychart
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Prev. Close
6.9967
Open
7.1138
High
7.2263
Low
6.9779
52 wk Range
3.21-8.4
Market Cap
1 754 M
Shares Outstanding
247 M
Revenue
428 M
EPS
-0.15
Beta
0.613
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Ardelyx Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Ardelyx Inc data using free add-ons & libraries
Get Ardelyx Inc Fundamental Data
Ardelyx Inc Fundamental data includes:
- Net Revenue: 428 M
- EBITDA: -34 049 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-01
- EPS/Forecast: -0.1429
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Ardelyx Inc News
New
Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF’s Spring Clinical Meetings
WALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines t...
Ardelyx reiterates 2026 guidance as IBSRELA targets $1B in 2029 while advancing ACCEL CIC Phase III enrollment by year-end
Earnings Call Insights: Ardelyx (ARDX) Q1 2026 MANAGEMENT VIEW * “2026 is poised to be another significant year of growth for our company, and we're already off to a great start,” said (Presid...
Ardelyx, Inc. Q1 2026 Earnings Call Summary
Ardelyx, Inc. Q1 2026 Earnings Call Summary - Moby Strategic Execution and Market Positioning Ibsrela revenue grew 58% year-over-year, driven by disciplined commercial execution and a strategy focus...
Ardelyx (ARDX) Q1 2026 Earnings Transcript
Image source: The Motley Fool. DATE Apr. 30, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Michael Raab Chief Commercial Officer — Eric Foster Chief Financial Officer — Su...
Get Ardelyx Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
